18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

EJNMMI Research

Table 1 Disease extent, measured metastatic sites and changes in mean SUVmax, PSA and ALP at 6 and 12 weeks after first administration of ²²³Ra

Subject (disease extent)	0 weeks				6 weeks			12 weeks
	Measured sites	Mean SUVmax (range)	Baseline PSA (ng/ml)	Baseline ALP (U/L)	SUV (range) [% of baseline]	PSA [% of baseline]	ALP [% of baseline]	SUV (range) [% of baseline]	PSA [% of baseline]	ALP [% of baseline]
A (6-20 metastases)	C6, T6, L Sacrum, R ilium, L femur	46.4 (33.1-75.3)	370	118	31.3 (26.5-40.5) [67.5%]	210 [56.8%]	47 [39.8%]	22.1 (16.7-28.2) [47.6%]	207 [55.9%]	53 [44.9%]
B (superscan)	C3, L1, L5, L femur, R tibia	15.0 (13.2-17.2)	508	761	16.0 (11.9-21.1) [106.7%]	459 [90.4%]	332 [43.6%]	3.7 (2.9-4.8) [24.7%]	350 [68.9%]	225 [29.6%]
C (6-20 metastases)	L1, L3, L5, sternum, R ischium	74.6 (54.7-98)	78	129	66.7 (51.3-76.7) [89.4%]	92 [117.9%]	85 [65.9%]	38.2 (26.5-46.9) [51.2%]	57 [73.1%]	70 [54.3%]
D (>20 metastases)	Skull, L scapula, T11, L3, L ilium	27.5 (20.3-35.4)	551	89	25.3 (20.6-29.5) [92%]	674 [122.3%]	53 [59.6%]	30.7 (21.1-59.4) [111.6%]	607 [110.2%]	50 [56.2%]
E (superscan)	Skull, T12, L3, R ilium, R femur	22.3 (11.4-28.6)	254	393	20.3 (11-25) [91%]	273 [107.5%]	406 [103.3%]	18.8 (9.8-24.8) [84.3%]	298 [117.3%]	290 [73.8%]